Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight loss of 15.7% at 68 weeks, which the firm believes is in line with expectations following the initial CagriSema Phase 3 obesity data in December and similar to Eli Lilly’s (LLY) Tirzepatide. The firm sees limited impact to Eli Lilly shares and says the focus remains on weekly scripts and Orfor Phase 3 data due in Q2. Morgan Stanley has an Overweight rating and $1,146 price target on Eli Lilly shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Incyte, Eli Lilly present results from Phase 3 BRAVE-AA-PEDS study
- Eli Lilly’s Ebglyss achieved ‘deep and sustained response’ in ADjoin study
- Teladoc announces pharmacy integration agreement with Gifthealth
- BofA says injunction denial ‘indirect negative’ for Hims & Hers
- Hims & Hers lower after judge denies compounders’ motion for injunction